Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
293M
-
Number of holders
-
163
-
Total 13F shares, excl. options
-
123M
-
Shares change
-
-6.08M
-
Total reported value, excl. options
-
$795M
-
Value change
-
-$50.6M
-
Put/Call ratio
-
0.65
-
Number of buys
-
74
-
Number of sells
-
-96
-
Price
-
$6.46
Significant Holders of AbCellera Biologics Inc. - Ordinary Shares (ABCL) as of Q2 2023
224 filings reported holding ABCL - AbCellera Biologics Inc. - Ordinary Shares as of Q2 2023.
AbCellera Biologics Inc. - Ordinary Shares (ABCL) has 163 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 123M shares
of 293M outstanding shares and own 41.87% of the company stock.
Largest 10 shareholders include BAILLIE GIFFORD & CO (26.4M shares), BAKER BROS. ADVISORS LP (16.5M shares), Voya Investment Management LLC (10.6M shares), Capital World Investors (8.42M shares), CREDIT SUISSE AG/ (4.57M shares), ORBIMED ADVISORS LLC (4.18M shares), ArrowMark Colorado Holdings LLC (4.11M shares), Founders Fund VII Management, LLC (3.77M shares), BlackRock Inc. (3.45M shares), and FEDERATED HERMES, INC. (3.37M shares).
This table shows the top 163 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.